MedTrace Logo

Evaluation of Patients With Covid-19 Infection in Terms of Severity of Osteoprosis

NCT05993130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2023-08-15

No results posted yet for this study

Summary

Osteoporosis is a condition characterized by decreased bone strength and an increased risk of fracture. Age, gender, body mass index, fragility fracture history, corticosteroid use, immobilization, smoking and alcohol use, endocrine pathologies besides inflammatory and infectious pathologies can also be effective in the development of osteoporosis. The aim of the study is to evaluate the effect of Covid-19 infection on the development of osteoporosis.

In this study, bone mineral density (BMD) measurements of patients with Covid-19 infection were examined. For this, dual-energy x-ray absorptiometry (DEXA) measurement was used. A total of 55 patients were included in the study and data such as age, height, weight, comorbidities, drugs used, and treatment methods were recorded. Results showed that the time spent in the intensive care unit was associated with the femoral neck T score in DEXA measurements of patients with Covid-19 infection. The use of drugs such as alendronate, zolendronate, denosumab or teriparatide during the treatment process did not have a statistically significant effect on the lumbar and femur T scores.

Conditions

  • Severity of Osteoprosis

Interventions

OTHER

The patients were not intervened. This is a retrospective study

The patients were not intervened. This is a retrospective study

Sponsors & Collaborators

  • Kayseri Education and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05993130 on ClinicalTrials.gov